Vaccine Effectiveness, School Reopening, and Risk of Omicron Infection Among Adolescents Aged 12-17 Years
{{output}}
Purpose: The BNT162b2 (Pfizer-BioNTech) is approved for adolescents aged 12-17 years. We estimated BNT162b2 vaccine effectiveness (VE) and a booster dose effectiveness in adolescents aged 12-17 years and the impact of opening sch... ...
